KD-025 (Nanjing KAEDI Biotech/Chinese Academy of Sciences)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameKD-025 (Nanjing KAEDI Biotech/Chinese Academy of Sciences)
Drug Alias Nameanti-NKG2D-ligand CAR T-cell therapy (Nanjing KAEDI Biotech/Chinese Academy of Sciences)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionNKG2D ligands modulators
TargetsNKG2D ligands
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsLiver Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Kaidi Medical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChinese Academy Of SciencesNanjing Kaidi Medical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian NeoplasmsLiver Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A